Pain Management in Pregnancy

Pain management in pregnancy concerns the assessment and treatment of pain in pregnant patients. It is a distinct topic within pain medicine because the physiological changes of pregnancy alter how analgesic drugs behave, and because most analgesics can cross the placenta, so that decisions must weigh relief of maternal pain against potential effects on fetal development and the newborn.

Definition

Pain management in pregnancy is the recognition, measurement, and treatment of acute and chronic pain in pregnant patients, accounting for pregnancy-related physiological change and for the potential effects of analgesics on the fetus and newborn through placental transfer.

Scope

This entry covers why pregnancy changes the risk-benefit balance of analgesia, the concept of placental transfer and fetal and neonatal effects, and the framing of these trade-offs in the clinical literature. It is a reference topic and does not provide dosing, drug selection, or individualized treatment advice.

Core questions

• How does pregnancy change the way analgesic drugs are handled by the body?
• What does it mean that most analgesics cross the placenta, and why does that matter?
• How is the balance weighed between relieving maternal pain and possible fetal or neonatal effects?
• What are recognized fetal and neonatal considerations associated with certain analgesics?

Key concepts

• Pregnancy-related physiological change
• Placental transfer of analgesics
• Maternal-fetal risk-benefit balance
• Fetal developmental considerations
• Neonatal effects of maternal analgesic use
• Avoiding both undertreatment and avoidable fetal risk

Mechanisms

Pregnancy alters analgesic decisions in two linked ways. Physiological changes across pregnancy affect how drugs are absorbed, distributed, and cleared, which can change the relationship between a dose and its effect in the mother. At the same time, most analgesics cross the placenta, so a drug given to treat maternal pain can reach the fetus, introducing the possibility of effects on development or on the newborn. These considerations mean that managing pain in pregnancy is framed as balancing adequate maternal analgesia against potential fetal and neonatal effects, with specific concerns documented for certain agents (Broussard et al., 2011; McQueen & Murphy-Oikonen, 2016).

Clinical relevance

Pain management in pregnancy is relevant across obstetric, surgical, and chronic-pain care, where both untreated maternal pain and avoidable fetal exposure carry concern. This entry is descriptive reference material about how the maternal-fetal balance is conceptualized in the literature; it is not a guide to drug choice or dosing and is not a substitute for clinical judgement.

Epidemiology

Pain is common during pregnancy, from musculoskeletal and other causes, and many pregnant patients use analgesics at some point. Population-based studies have examined associations between maternal analgesic use and outcomes such as birth defects (Broussard et al., 2011), and prolonged maternal opioid use is recognized in relation to neonatal abstinence syndrome (McQueen & Murphy-Oikonen, 2016), which together inform how the risk-benefit balance is framed.

History

Caution about drug use in pregnancy intensified after twentieth-century experiences showing that maternal medication could affect the fetus, which shaped how analgesia in pregnancy is approached. Subsequent population-based research examined associations between maternal analgesic use and developmental outcomes (Broussard et al., 2011), and the recognition of neonatal abstinence syndrome with prolonged maternal opioid use (McQueen & Murphy-Oikonen, 2016) further defined the considerations clinicians weigh, within the broader principle that maternal pain itself should not be neglected (Brennan, Carr & Cousins, 2007).

Key figures

• Cheryl Broussard
• Karen McQueen
• Margaret Honein

Seminal works

• broussard-2011
• mcqueen-2016
• brennan-2007

Frequently asked questions

Why is treating pain in pregnancy more complicated?

Pregnancy changes how the body handles drugs, and most analgesics cross the placenta and can reach the fetus. Decisions therefore weigh relief of maternal pain against potential effects on the fetus and newborn. The entry describes this balance rather than recommending specific drugs or doses.

Does this mean pain should be left untreated during pregnancy?

No. The literature emphasizes that untreated maternal pain is itself a concern and that the goal is to balance adequate relief against avoidable fetal risk. The entry is reference material and does not provide individualized treatment advice.